Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. - Wikidata - awgldk - TriplyDB

Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.

Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.

http://www.wikidata.org/entity/Q35146923

about

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma.An Acetamide Derivative as a Camptothecin Sensitizer for Human Non-Small-Cell Lung Cancer Cells through Increased Oxidative Stress and JNK Activation.Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis.Restoration of Peripheral Intermediate and Classical Monocytes Expressing HLA-DR in Patients With Lung Adenocarcinoma After Platinum-Based Chemotherapy.Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer

P2860

Q36334926-FDD1BE5D-7177-4725-A247-06A781025FC9 Q36741073-0F545D9D-2BFA-4DF5-A871-763F95C2180F Q37397101-99FB515E-5AA9-4839-A534-3D7C8C51D819 Q38143201-B7AF87F6-6439-4325-A117-6F1082E68F65 Q39007756-8CBF0AB4-5540-423A-BCE0-1BBCBA1D0EDD Q55278816-86E032C2-275E-4323-BCDD-AA4BC7FA91D9 Q57176872-CFF7F1D1-DA39-48FC-8A4B-12FA14860D9C

P2860

Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.

http://www.wikidata.org/entity/Q35146923

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Maintenance therapy in advance ...... on, tolerability and outcomes.

@ast

Maintenance therapy in advance ...... on, tolerability and outcomes.

@en

type

label

Maintenance therapy in advance ...... on, tolerability and outcomes.

@ast

Maintenance therapy in advance ...... on, tolerability and outcomes.

@en

prefLabel

Maintenance therapy in advance ...... on, tolerability and outcomes.

@ast

Maintenance therapy in advance ...... on, tolerability and outcomes.

@en

P1433

Q35146923-077C89E1-AD1F-44BB-8553-6E22B0832434

P1476

Q35146923-0626BAC1-C4E2-4E20-B63C-A0AD9A3E6146

P2093

Q35146923-6DB70919-ED5C-443D-B019-A38C14A167A8

Q35146923-CD3931F2-0290-40A0-8BFA-31F699B79FCE

P2860

Q35146923-047068D3-EC95-4B27-A98A-82EE801656F4

Q35146923-145ACC71-D4B4-4E4C-A35F-03693A4EEBDC

Q35146923-14B3EF01-A99C-4E22-A8E6-37C57A16CA8D

Q35146923-16302B2F-6222-4AD3-B15C-B5CE530940DD

Q35146923-1D5F0810-5377-4B62-9C1E-A7D4A67CF8DB

Q35146923-47EE30AC-5C71-4183-AF72-146222A9DBE8

Q35146923-4BC7CE89-4364-49EF-A23E-3CA92EBADFE4

Q35146923-648158D6-481D-417F-803F-9E72C65C18A1

Q35146923-66EB034A-0C27-49A7-9A24-7676FBA6E91B

Q35146923-6925D86E-1833-4AC5-83E9-A61CBE63C3D4

P304

Q35146923-9C7755AB-DFE4-4388-9D65-577ABDA0F01D

P31

Q35146923-C3EA673B-E54F-4048-9F7F-FC2E1C4446D3

P356

Q35146923-0F27188D-4800-467A-8300-8EDD63D648CB

P433

Q35146923-21722941-57DB-4101-A359-DCE2024B1FA4

P478

Q35146923-ED3632E2-C09A-4877-9621-9FEF82CA1912

P577

Q35146923-7AA124B0-50F8-45B7-8439-39A417DD6D61

P5875

Q35146923-76C9DA43-D66C-4F06-A275-B8F7DD44AA76

P698

Q35146923-2AC9F573-D782-4F15-B8A5-E9E27B5E5072

P932

Q35146923-2C22A36D-6D38-477D-AA44-804A3B856F63

P356

1758834011399306

P1433

Therapeutic advances in medical oncology

P1476

Maintenance therapy in advance ...... on, tolerability and outcomes.

@en

P2093

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

Linda E Coate

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

P304

139-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834011399306

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51636182

http://www.w3.org/2001/XMLSchema#string

P698

21904577

http://www.w3.org/2001/XMLSchema#string

P932

3150062

http://www.w3.org/2001/XMLSchema#string